Evidence map›Paper›PMID 35071609›Full record

ReviewFuture journal of pharmaceutical sciences2022

Pharmaceutical nanotechnology: from the bench to the market.

Zaed M Mazayen, Amira M Ghoneim, Rasha S Elbatanony, Emad B Basalious, Ehab R Bendas

Abstract readReview
In one paragraph

Review in Future journal of pharmaceutical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Nanoformulations in epilepsy therapy - a systematic review of emerging strategies in status epilepticus.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zaed M MazayenFaculty of Pharmacy, Department of Pharmaceutical Technology, Future University in Egypt, Cairo, 11835 Egypt.
Amira M GhoneimFaculty of Pharmacy, Department of Pharmaceutical Technology, Future University in Egypt, Cairo, 11835 Egypt.
Rasha S ElbatanonyFaculty of Pharmacy, Department of Pharmaceutical Technology, Future University in Egypt, Cairo, 11835 Egypt.
Emad B BasaliousFaculty of Pharmacy, Department of Pharmaceutics and Industrial Pharmacy, Cairo University, Cairo, Egypt.
Ehab R BendasFaculty of Pharmacy, Department of Pharmaceutical Technology, Future University in Egypt, Cairo, 11835 Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNanotechnology is considered a new and rapidly emerging area in the pharmaceutical and medicinal field. Nanoparticles, as drug delivery systems, impart several advantages concerning improved efficacy as well as reduced adverse drug reactions. MAIN BODY: Different types of nanosystems have been fabricated including carbon nanotubes, paramagnetic nanoparticles, dendrimers, nanoemulsions, etc. Physicochemical properties of the starting materials and the selected method of preparation play a significant aspect in determining the shape and characteristics of the developed nanoparticles. Dispersion of preformed polymers, coacervation, polymerization, nano-spray drying and supercritical fluid technology are among the most extensively used techniques for the preparation of nanocarriers. Particle size, surface charge, surface hydrophobicity and drug release are the main factors affecting nanoparticles physical stability and biological performance of the incorporated drug. In clinical practice, many nanodrugs have been used for both diagnostic and therapeutic applications and are being investigated for various indications in clinical trials. Nanoparticles are used for the cure of kidney diseases, tuberculosis, skin conditions, Alzheimer's disease, different types of cancer as well as preparation of COVID-19 vaccines.

conclusionIn this review, we will confer the advantages, types, methods of preparation, characterization methods and some of the applications of nano-systems.

Indexed as

ApplicationsCharacterizationDelivery systemsFabricationNanotechnology

Identifiers

PMID35071609
PMCPMC8760885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.